Use of lipid conjugates in the treatment of diseases or disorders of the eye

Abstract

In one embodiment, the invention provides a method of treating, reducing the incidence, reducing the severity or pathogenesis of an eye disease or disorder in a subject, including, inter alia, retinal detachment, macular degeneration, glaucoma or retinopathy, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a contact lens solution comprising a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.

What we claim is: 
     
         1 . A method of treating a disease or disorder of the eye in a subject comprising the step of contacting said subject with a compound comprising a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. 
     
     
         2 . The method according to  claim 1 , wherein said phospholipid moiety is phosphatidylethanolamine. 
     
     
         3 . The method according to  claim 2 , wherein said phosphatidylethanolamine is dipalmitoyl phosphatidylethanolamine. 
     
     
         4 . The method according to  claim 2 , wherein said phosphatidylethanolamine is dimyristoyl phosphatidylethanolamine 
     
     
         5 . The method according to  claim 1 , wherein said physiologically acceptable monomer, dimer, oligomer, or polymer is polygeline. 
     
     
         6 . The method according to  claim 1 , wherein said physiologically acceptable monomer, dimer, oligomer, or polymer is a polypyranose. 
     
     
         7 . The method according to  claim 6 , wherein said polypyranose is carboxymethylcellulose. 
     
     
         8 . The method according to  claim 6 , wherein said polypyranose is alginate. 
     
     
         9 . The method according to  claim 6 , wherein said polypyranose is hydroxyethyl starch. 
     
     
         10 . The method according to  claim 1 , wherein the lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof is represented by the structure of the general formula (A): 
       
         
           
           
               
               
           
         
         wherein 
         L is a lipid or a phospholipid; 
         Z is either nothing, ethanolamine, serine, inositol, choline, phosphate, or glycerol; 
         Y is either nothing or a spacer group ranging in length from 2 to 30 atoms; 
         X is a physiologically acceptable polymer; and 
         n is a number from 2 to 1000. 
       
     
     
         11 . The method of  claim 10 , wherein L is phosphatidyl, Z is ethanolamine, Y is nothing, and X is carboxymethylcellulose or a glycosaminoglycan. 
     
     
         12 . The method of  claim 10 , wherein the phosphatidylethanolamine moiety is dipalmitoyl or dimyristoyl phosphatidylethanolamine. 
     
     
         13 . The method of  claim 10 , wherein the lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof is represented by the structure of the general formula (I): 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; 
         R 2  is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; and 
         Y is either nothing or a spacer group ranging in length from 2 to 30 atoms; 
         X is a physiologically acceptable polymer; and 
         n is a number from 1 to 1000. 
       
     
     
         14 . The method of  claim 13 , wherein n is a number from 2 to 100. 
     
     
         15 . The method of  claim 10 , wherein the lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof is represented by the structure of the general formula (III): 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; 
         R 2  is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; 
         Z is either nothing, inositol, choline, or glycerol; 
         Y is either nothing or a spacer group ranging in length from 2 to 30 atoms; 
         X is a glycosaminoglycan; and 
         n is a number from 1 to 1000. 
       
     
     
         16 . The method of  claim 15 , wherein n is a number from 2 to 100. 
     
     
         17 . The method of  claim 10 , wherein the lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof is represented by the structure of the general formula (IV): 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is either hydrogen or a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; 
         R 2  is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; 
         Z is either nothing, inositol, choline, or glycerol; 
         Y is either nothing or a spacer group ranging in length from 2 to 30 atoms; 
         X is a glycosaminoglycan; and 
         n is a number from 1 to 1000. 
       
     
     
         18 . The method of  claim 17 , wherein n is a number from 2 to 100. 
     
     
         19 . The method of  claim 10 , wherein the lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof is represented by the structure of the general formula (V): 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; 
         R 2  is either hydrogen or a linear, saturated, mono-unsaturated, or poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon atoms; 
         Z is either nothing, inositol, choline, or glycerol; 
         Y is either nothing or a spacer group ranging in length from 2 to 30 atoms; 
         X is a glycosaminoglycan; and 
         n is a number from 1 to 1000. 
       
     
     
         20 . The method of  claim 19 , wherein n is a number from 2 to 100.